[go: up one dir, main page]

AR002245A1 - Antagonistas del receptor de adhesion, procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos parapreparar medicamentos. - Google Patents

Antagonistas del receptor de adhesion, procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos parapreparar medicamentos.

Info

Publication number
AR002245A1
AR002245A1 ARP950100091A AR10009195A AR002245A1 AR 002245 A1 AR002245 A1 AR 002245A1 AR P950100091 A ARP950100091 A AR P950100091A AR 10009195 A AR10009195 A AR 10009195A AR 002245 A1 AR002245 A1 AR 002245A1
Authority
AR
Argentina
Prior art keywords
prepare
antagonists
procedure
contain
same
Prior art date
Application number
ARP950100091A
Other languages
English (en)
Inventor
Joachim Prof Gante
Horst Dr Juraszyk
Peter Dr Raddatz
Hanns-Bernotat Wurziger
Sabine Dr Danielowski
Guido Dr Melzer
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR002245A1 publication Critical patent/AR002245A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

El invento se refiere a los compuestos de fórmula (I), en la que X es O, S, NH, o NA, Y es aziridino, azetidino, pirrolidino, piperidino, hexahidroazepinopiperacino sustituido con R2, R1 es(II)ó(II); R2 es -CrH2r-COOR3; R3 es H,A o Ar;A es alquilo;B es H, A, cicloalquilo de 3 a 7 miembros Ar-CkH2k- o amidino,Ar es fenilo o bencilo sustituido o nó, con A,Cl,Br, I, NO2, CN, OA, OH, NH2, NHA y/o NA2; k es 1, 2, 3 ó 4; m y r son 0, 1, 2, 3, ó 4; y n es 2, 3 ó 4. Loscompuestos del invento inhibenla unión de fibrinógeno a su receptor correspondiente, y pueden ser empleados para el tratamiento de trombosis,osteoporosis, enfermedades tumorales, apoplejías, infarto del miocardio, infecciones, arteriosclerosis y enfermedades osteolíticas.
ARP950100091A 1994-11-08 1995-11-08 Antagonistas del receptor de adhesion, procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos parapreparar medicamentos. AR002245A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4439846A DE4439846A1 (de) 1994-11-08 1994-11-08 Adhäsionsrezeptor-Antagonisten

Publications (1)

Publication Number Publication Date
AR002245A1 true AR002245A1 (es) 1998-03-11

Family

ID=6532768

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP950100091A AR002245A1 (es) 1994-11-08 1995-11-08 Antagonistas del receptor de adhesion, procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos parapreparar medicamentos.

Country Status (22)

Country Link
US (1) US5776937A (es)
EP (1) EP0711770A1 (es)
JP (1) JPH08208629A (es)
KR (1) KR100384978B1 (es)
CN (1) CN1069640C (es)
AR (1) AR002245A1 (es)
AU (1) AU704184B2 (es)
BR (1) BR9505109A (es)
CA (1) CA2162223A1 (es)
CO (1) CO4520229A1 (es)
CZ (1) CZ291049B6 (es)
DE (1) DE4439846A1 (es)
FI (1) FI955351A7 (es)
HU (1) HU217085B (es)
NO (1) NO306113B1 (es)
PL (1) PL183595B1 (es)
RU (1) RU2155762C2 (es)
SK (1) SK281815B6 (es)
TR (1) TR199501389A2 (es)
TW (1) TW316903B (es)
UA (1) UA41928C2 (es)
ZA (1) ZA959434B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
ES2123889T3 (es) * 1994-11-02 1999-01-16 Merck Patent Gmbh Antagonistas de receptores de adhesion.
US6046331A (en) * 1998-12-17 2000-04-04 Synaptic Pharmaceutical Corporation Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
IL143901A0 (en) 1998-12-23 2002-04-21 Searle & Co Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
WO2000045177A1 (en) 1999-01-27 2000-08-03 Pharmacia & Upjohn Company Assays for modulators of elongation factor p activity
JP2005515029A (ja) * 2002-01-22 2005-05-26 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 感染症耐性医療機器
AU2003275480A1 (en) * 2002-10-07 2004-05-04 Smithkline Beecham Corporation Compounds
MXPA05006885A (es) * 2002-12-24 2005-08-16 Sankyo Co Derivado de dihidropiridina opticamente activo.
CN102796091A (zh) * 2011-05-24 2012-11-28 北大方正集团有限公司 取代的噁唑烷酮化合物及其制备方法和应用
KR20150075091A (ko) * 2012-10-29 2015-07-02 에프. 호프만-라 로슈 아게 3,4-이치환된 옥사졸리디논 유도체 및 칼슘 활성화 칼륨 채널의 억제제로서 이의 용도
CN104230915B (zh) * 2014-08-29 2016-08-17 南京大学 含噻唑烷二酮的苯基哌嗪衍生物及其制备方法与用途
ES2919779T3 (es) 2017-06-20 2022-07-28 Imbria Pharmaceuticals Inc Derivado de 1-[(2,3,4-trimetoxifenil)metil]-piperazina, composiciones del mismo y métodos para aumentar la eficiencia del metabolismo cardíaco
EP4497474A3 (en) 2018-10-17 2025-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3723797A1 (de) * 1987-07-18 1989-01-26 Merck Patent Gmbh Oxazolidinone
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US4948801A (en) * 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DE4005371A1 (de) * 1990-02-21 1991-08-22 Merck Patent Gmbh Oxazolidinone
DE4017211A1 (de) * 1990-05-29 1991-12-05 Merck Patent Gmbh Oxazolidinone
ATE181735T1 (de) * 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
DE4405633A1 (de) * 1993-05-01 1994-11-03 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III

Also Published As

Publication number Publication date
AU704184B2 (en) 1999-04-15
NO954458D0 (no) 1995-11-07
TR199501389A2 (tr) 1996-07-21
KR960017663A (ko) 1996-06-17
UA41928C2 (uk) 2001-10-15
EP0711770A1 (de) 1996-05-15
SK136895A3 (en) 1996-06-05
RU2155762C2 (ru) 2000-09-10
AU3661895A (en) 1996-05-23
BR9505109A (pt) 1997-09-09
FI955351L (fi) 1996-05-09
KR100384978B1 (ko) 2003-09-02
NO954458L (no) 1996-05-09
DE4439846A1 (de) 1996-05-09
NO306113B1 (no) 1999-09-20
ZA959434B (en) 1996-05-15
TW316903B (es) 1997-10-01
JPH08208629A (ja) 1996-08-13
CZ288895A3 (en) 1996-06-12
CO4520229A1 (es) 1997-10-15
CN1132201A (zh) 1996-10-02
HU217085B (hu) 1999-11-29
CZ291049B6 (cs) 2002-12-11
HU9503191D0 (en) 1996-01-29
CN1069640C (zh) 2001-08-15
FI955351A7 (fi) 1996-05-09
PL311257A1 (en) 1996-05-13
SK281815B6 (sk) 2001-08-06
US5776937A (en) 1998-07-07
CA2162223A1 (en) 1996-05-09
FI955351A0 (fi) 1995-11-07
PL183595B1 (pl) 2002-06-28
HUT76052A (en) 1997-06-30

Similar Documents

Publication Publication Date Title
AR002245A1 (es) Antagonistas del receptor de adhesion, procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos parapreparar medicamentos.
AR007160A1 (es) Compuestos antagonistas del receptor de adhesion, procedimiento para preparar estos compuestos y preparaciones farmaceuticas que los contienen
CL2003002756A1 (es) Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia.
ATE297203T1 (de) Antithrombotische mitteln
AR003121A1 (es) Antagonistas del receptor de adhesión, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y su empleo para preparar medicamentos y combatir enfermedades
ES2053451T3 (es) Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles.
YU157191A (sh) Antagonisti receptora fibrinogena
DE69325130D1 (de) N-sulfonyl-2-oxoindol-derivate mit einer affinität für die vasopressin und/oder ocytocin rezeptoren
NO955256D0 (no) Fenylheterosykluser som syklooksygenase-2-inhibitorer
MX9504630A (es) Nuevos derivados de la oxazolidinona, antagonista del receptor de adhesion, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
NO931695L (no) Nye 4-arylpiperaciner og 4-arylpiperidiner
DK51986A (da) Heterocycliske forbindelser, deres fremstilling og anvendelse som insecticide midler
MY133897A (en) N-(4-carb-amimidophenyl) glycineamide derivatives
DK0920421T3 (da) Isoxazolinderivater anvendelige som antimikrobielle midler
NO951645L (no) Syklopeptider
TR199701645A2 (xx) Vitronektin resept�r antagonistleri,bunlar�n imalat� ve kullan�m�
BG99863A (bg) Антагонисти на фибриногеновия рецептор
ES2156255T3 (es) Procedimiento para preparar antagonistas del receptor de fibrinogeno.
ATE253359T1 (de) Antithrombotische mittel
UY27324A1 (es) Nuevas sales de napsilato i
SE9902387D0 (sv) New pharmaceutically active compounds
PA7801701A1 (es) Compuestos ariltios
UY26329A1 (es) Antagonistas de los receptores de vitronectina
DE69828522D1 (de) Antithrombotische mittel
ES2127758T3 (es) Nuevos inhibidores de la alfa-manosidasa.